Prostaglandin E2 at new glance: Novel insights in functional diversity offer therapeutic chances

International Journal of Biochemistry and Cell Biology

Volumn 42, Issue 2, 2010, Pages 198-201

  Legler, Daniel F ^a,b   Bruckner, Markus ^a   Uetz von Allmen, Edith ^a   Krause, Petra ^a  

^a UNIVERSITY OF KONSTANZ   (Switzerland)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

Aspirin; Cyclooxygenase; Eicosanoid

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 3; CYTOKINE; ETORICOXIB; FLURBIPROFEN; G PROTEIN COUPLED RECEPTOR; GLUCOCORTICOID; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E RECEPTOR BLOCKING AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN E2 ANTIBODY; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; UNCLASSIFIED DRUG; VALDECOXIB;

ALZHEIMER DISEASE; AUTOCRINE EFFECT; BLOOD PRESSURE REGULATION; CHRONIC INFLAMMATION; DISEASE COURSE; DISEASE SEVERITY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; FERTILITY; GASTROINTESTINAL TRACT FUNCTION; HUMAN; HYPERALGESIA; IMMUNOREGULATION; IMMUNOSURVEILLANCE; INFLAMMATION; LIPID OXIDATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PARACRINE SIGNALING; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; PROTEIN INTERACTION; SHORT SURVEY; TUMOR; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG ANTAGONISM; DRUG DEVELOPMENT; ENZYME SPECIFICITY; GENE EXPRESSION REGULATION; METABOLISM; REVIEW;

ANIMALS; DINOPROSTONE; DRUG DISCOVERY; GENE EXPRESSION REGULATION; HUMANS; RECEPTORS, PROSTAGLANDIN E; SUBSTRATE SPECIFICITY;

EID: 73749088151     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2009.09.015     Document Type: Short Survey

References (21)

1. + T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res 68 (2008) 7520-7529
2. + T cells. J Immunol 175 (2005) 1483-1490
3. Boneberg E.M., Legler D.F., Senn H.J., and Furstenberger G. Reduced expression of cyclooxygenase-2 in primary breast cancer. J Natl Cancer Inst 100 (2008) 1042-1043
4. Dey I., Lejeune M., and Chadee K. Prostaglandin E2 receptor distribution and function in the gastrointestinal tract. Br J Pharmacol 149 (2006) 611-623
5. Fortier M.A., Krishnaswamy K., Danyod G., Boucher-Kovalik S., and Chapdalaine P. A postgenomic integrated view of prostaglandins in reproduction: implications for other body systems. J Physiol Pharmacol 59 Suppl 1 (2008) 65-89
6. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 (2001) 1871-1875
7. Greenhough A., Smartt H.J., Moore A.E., Roberts H.R., Williams A.C., Paraskeva C., et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30 (2009) 377-386
8. Harris S.G., Padilla J., Koumas L., Ray D., and Phipps R.P. Prostaglandins as modulators of immunity. Trends Immunol 23 (2002) 144-150
9. Kabashima K., Sakata D., Nagamachi M., Miyachi Y., Inaba K., and Narumiya S. Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat Med 9 (2003) 744-749
10. Krause P., Bruckner M., Uermosi C., Singer E., Groettrup M., and Legler D.F. Prostaglandin E2 enhances T cell proliferation by inducing the co-stimulatory molecules OX40L, CD70 and 4-1BBL on dendritic cells. Blood 113 (2009) 2451-2460
11. Kunikata T., Yamane H., Segi E., Matsuoka T., Sugimoto Y., Tanaka S., et al. Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3. Nat Immunol 6 (2005) 524-531
12. Legler D.F., Krause P., Scandella E., Singer E., and Groettrup M. Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol 176 (2006) 966-973
13. Muthuswamy R., Urban J., Lee J.J., Reinhart T.A., Bartlett D., and Kalinski P. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res 68 (2008) 5972-5978
14. Park J.Y., Pillinger M.H., and Abramson S.B. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin Immunol 119 (2006) 229-240
15. Samuelsson B., Morgenstern R., and Jakobsson P.J. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 59 (2007) 207-224
16. Simmons D.L., Botting R.M., and Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56 (2004) 387-437
17. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69 (2000) 145-182
18. Sugimoto Y., and Narumiya S. Prostaglandin E receptors. J Biol Chem 282 (2007) 11613-11617
19. Tai H.H., Cho H., Tong M., and Ding Y. NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions. Curr Pharm Des 12 (2006) 955-962
20. Wang M.T., Honn K.V., and Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metast Rev 26 (2007) 525-534
21. Yao C., Sakata D., Esaki Y., Li Y., Matsuoka T., Kuroiwa K., et al. Prostaglandin E(2)-EP4 signaling promotes immune inflammation through T(H)1 cell differentiation and T(H)17 cell expansion. Nat Med 15 (2009) 633-640